# A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

> **NCT03606057** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 188 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64565111
- **DRUG:** Moxifloxacin
- **DRUG:** JNJ-64565111-matching Placebo
- **DRUG:** Moxifloxacin-matching Placebo

## Key facts

- **NCT ID:** NCT03606057
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-13
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-02-28
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606057, "A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03606057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*